Skip to content
DataLookout
Menu

PERFORMANCT07795164

Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 2 with changes below, 1 re-verified with no change.

  1. Minor Trial sites expanded: 9 → 62 locations
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Clinical Outcome Event
Timeframe: Baseline through end of study (approximately Month 60)
Histological Response: MASH resolution
Timeframe: Baseline through Week 52
Histological Response: Fibrosis improvement
Timeframe: Baseline through Week 52

Secondary (11)

Histologic Response: Proportion of subjects achieving both MASH resolution (according to NASH CRN classification) without worsening of fibrosis and ≥ 1 stage improvement in liver fibrosis without worsening of MASH
HistoIndex qFibrosis: Proportion of subjects with at least a 1 stage improvement in qFibrosis
Anthropometric parameters: Relative (%) change from baseline in body weight (kg)
Anthropometric parameters: Relative (%) change from baseline in body mass index (BMI; kg/m2)
Anthropometric parameters: Relative (%) change from baseline in waist circumference (cm)
Show 6 moreShow less
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in alanine aminotransferase (ALT; U/L)
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in enhanced liver fibrosis (ELF) score
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Relative (%) change from baseline in vibration controlled transient elastography (VCTE; kPa) by Fibroscan
HRQoL: Change from baseline in core symptoms of MASH on the NASH-CHECK questionnaire.
HRQoL: Change from baseline in Short-form 36 (SF-36) summary scores.
HRQoL: Change from baseline in Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) domain scores.

Arms and interventions

Pemvidutide 1.8 mgExperimental
Pemvidutide 2.4 mgExperimental
PlaceboPlacebo comparator

Drugs: Pemvidutide

Other: Placebo

Sites

62 sites in 2 countries

United States 61, Puerto Rico 1